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Abstract
Background: Bone marrow -derived cells (BMDCs) can either limit or contribute to the process
of pulmonary vascular remodeling. Whether the difference in their effects depends on the
mechanism of pulmonary hypertension (PH) remains unknown.
Objectives: We investigated the effect of BMDCs on PH induced in mice by either monocrotaline
or exposure to chronic hypoxia.
Methods: Intravenous administration of the active monocrotaline metabolite (monocrotaline
pyrrole, MCTp) to C57BL/6 mice induced PH within 15 days, due to remodeling of small distal
vessels. Three days after the MCTp injection, the mice were injected with BMDCs harvested from
femurs and tibias of donor mice treated with 5-fluorouracil (3.5 mg IP/animal) to deplete mature
cells and to allow proliferation of progenitor cells.
Results: BMDCs significantly attenuated PH as assessed by reductions in right ventricular systolic
pressure (20 ± 1 mmHg vs. 27 ± 1 mmHg, P ≤ 0.01), right ventricle weight/left ventricle+septum
weight ratio (0.29 ± 0.02 vs. 0.36 ± 0.01, P ≤ 0.03), and percentage of muscularized vessels (26.4%
vs. 33.5%, P ≤ 0.05), compared to control animals treated with irradiated BMDCs. Tracking cells
from constitutive GFP-expressing male donor mice with anti-GFP antibodies or chromosome Y
level measurement by quantitative real-time PCR showed BMDCs in the lung. In contrast,
chronically hypoxic mice subjected to the same procedure failed to show improvement in PH.
Conclusion: These results show that BMDCs limit pulmonary vascular remodeling induced by
vascular injury but not by hypoxia.
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Background
Several reports suggests that bone marrow-derived cells
(BMDCs) are able to colonize the adult lung following
injury. In mice subjected to total body irradiation, trans-
plantation of a single donor marrow-derived stem cell was
followed by engraftment and differentiation to non-
hematopoietic tissues, including lung tissue [1]. Follow-
ing bleomycin-induced injury in mice, mesenchymal
stem cells colonized the lung and differentiate into type 1
or type II pneumocytes [2,3]. In addition, human studies
after hematopoietic stem cell transplantation or lung
transplantation have shown significant chimerism, partic-
ularly in epithelial and endothelial cells [4-7]. However,
these results have not always be confirmed by more recent
articles using multiple methods of engraftment assess-
ment [8].
Whether BMDCs participate in the growth, repair, or
homeostasis of the lung vasculature and, consequently, in
endothelial cell differentiation and vascular remodeling
after vascular injury is still a matter of debate. Using the rat
model of monocrotaline (MCT)-induced pulmonary
hypertension, Zhao et al. [9] showed that bone marrow-
derived endothelial like progenitor cells protected against
pulmonary hypertension and pulmonary artery muscular-
ization and this effect is enhanced when cells were trans-
fected with eNOS gene. The presence of BMDCs in the
pulmonary vasculature of mice exposed to chronic
hypoxia, as well as in the smooth muscle coat of pulmo-
nary arteries from patients with chronic obstructive pul-
monary disease, has been considered evidence that
progenitor cells contribute to pulmonary vascular remod-
eling [10,11]. Into the opposite, in a pneumonectomy
model of lung growth in mice, Voswinckel et al. [12]
found no evidence of endothelial cell engraftment and
O'Neill and coll [13] failed to show any engraftment of
BMDCs in a model of hypoxia-mediated angiogenesis in
the mouse spinotrapezius muscle. Moreover, GM-CSF
induces a 23% increased in angiogenesis without evidence
of bone marrow cells contribution to endothelium
remodeling.
In the present study, we investigated whether BMDCs
injected to mice modified the development of PH induced
either by exposure to chronic hypoxia or by treatment
with the active MCT metabolite MCT pyrrole (MCTp). In
order to determine whether PH alterations were due to
protection of the pulmonary vasculature by BMDCs, we
used quantitative real-time PCR to detect lung cell engraft-
ment and measured lung eNOS expression in each exper-
imental condition.
Materials and methods
Animals
Wild-type C57BL/6J mice (Charles River Laboratories)
and transgenic eGFP C57BL/6-TgN mice (a gift from
Genopole, Evry, France) were used at 6–8 weeks of age.
Animal care and procedures were in accordance with insti-
tutional guidelines. Female mice were injected via the tail
vein with BMDCs harvested from male eGFP transgenic
mice treated by intraperitoneal injection of 3.5 mg 5-
fluorouracil (TEVA Pharma, Courbevoie, France) 3 days
before [14]. In a second set of experiments, female mice
were injected via the tail vein with immunomagnetically
purified Lin – BMDCs from eGFP male mice, cell sorted
on their CD45 expression in order to purify CD45-lin- or
CD45+lin- cells. The lineage markers used for depletion
were B220, CD3, CD5, Gr1, Mac1 and Ter 119 as previ-
ously described.
Pulmonary hypertension models
Mice were either exposed to chronic hypoxia (10 % FiO2
for 15 days as previously described) or given MCTp.
MCTp treatment was previously demonstrated as able to
induce pulmonary hypertension in rats, we then decided
to test this approach in mice. Monocrotaline (MCT)
(Sigma-Aldrich, Lyon, France) was converted to MCTp
using the method of Mattocks et al. [15]. MCTp was dis-
solved in N, N-dimethylformamide (DMF)/RPMI 1640
just before use. Animals were anesthetized with isoflurane
(Forene®, Abbott, Queenborough, UK) in a cylindrical
chamber and given a single injection of MCTp (5 mg/kg)
into a tail vein. In previous experiments, we found that
this treatment was followed within 15 days by moderate
pulmonary inflammation and remodeling of the small
distal vessels.
Study protocol
Mice were divided in seven groups: 1) vehicle-injected
mice maintained in room air; 2) MCTp-treated mice; 3)
MCTp-treated mice injected 3 days later with BMDCs; 4)
MCTp-treated mice injected 3 days later by irradiated (50
Grays) BMDCs 5) hypoxia-exposed mice 6) hypoxia-
exposed mice injected 3 days later with BMDCs; and 7)
hypoxia-exposed mice injected 3 days later with irradiated
BMDCs.
Assessment of pulmonary hypertension
Right ventricular systolic pressure (RVSP) and the right
ventricle/left ventricle+septum weight ratio (RV/LV+S)
were measured as previously described [16]. After fixation
and paraffin embedding, 5 µm-thick lung sections were
cut and stained with hematoxylin-phloxine-saffron. In
each mouse, 30 intraacinar vessels accompanying alveolar
ducts or alveoli were examined by an observer blinded to
the treatment.Respiratory Research 2007, 8:8 http://respiratory-research.com/content/8/1/8
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Assessment of donor cell colonization
For recipient of GFP marrow cells, immunohistochemis-
try was performed using rabbit polyclonal anti-GFP anti-
body (Abcam, Cambridge, UK), to detect donor cells. The
final reaction product was visualized with 3,3'-diami-
nobenzidine (DAB, Sigma, St Louis, USA). Sections were
counterstained with hematoxylin.
Quantification of murine Y chromosome in lung tissue
was achieved by quantitative real-time polymerase chain
reaction (PCR): first, DNA was extracted and purified
from mouse lung, previously washed-out from blood,
using the DNeasy tissue kit (Qiagen, Courtaboeuf,
France), then real-time PCR was carried out on a 7700-
sequence detection system with SYBR Green detection kit
(Applied Biosystems, Foster City, USA), using the follow-
ing PCR primers purchased from Invitrogen (Cergy Pon-
toise, France): Forward 5'-AGG TCC TGC TCC TTC CTT
TTG- 3'; and Reverse 5'-GCT TTC TCC TTC CTG ACA CAC
TAC A- 3'. Primer sequences were based on data published
by Gubbay et al. [17] and established using Blast software
on the Mus musculus domesticus sex-determining region
(Sry) gene AF009519 (National Institutes of Health, NIH,
Bethesda, USA). These primers amplify a 24-bp product.
Standard curves were generated by serially diluting male
mouse genomic DNA prepared from lung tissue.
eNOS expression detection
Immediately after removal, the lungs were quickly frozen
in liquid nitrogen. After thawing at 0°C, the tissues were
sonicated in 0.1 mM PBS containing antiproteases (1 µM
leupeptin and 1 µM pepstatin A) and CHAPS (20 mmol/
L) and the homogenate was centrifuged at 3,000 g for 10
min at 5°C. Western Blot analysis was then performed as
previously described [16]. Finally, eNOS immunoreactiv-
ity was quantified using a semi-automated image analysis
device (GeneTools, Syngene). Results are reported in arbi-
trary units.
Statistical analysis
All results are reported as means ± SEMs. One-way analy-
sis of variance (Kruskal-Wallis) was performed, and the
Mann Whitney test was used to identify significant
between-group differences. P values ≤ 0.05 were consid-
ered statistically significant.
Results
Effects of bone marrow-derived cells on monocrotaline-
induced pulmonary hypertension (PH)
PH developed within 15 days of MCTp injection, as
shown by a sustained increase in right ventricular systolic
pressure (RVSP), RV/LV+S, and muscularization of distal
pulmonary vessels, compared to vehicle-injected animals
(Fig. 1). BMDCs injection 3 days after MCTp injection
reduced the increases in RVSP and RV/LV+S in a dose-
dependent manner. As shown in Fig. 2, a BMDCs number
greater than 2.5·106 was needed to reduce RV pressure
and hypertrophy, and no additional benefit was obtained
by doubling the amount of BMDCs. Low BMDC doses
(3.5·105 cells) had no effect on RVSP or RV/LV+S. More-
over control irradiated BMDCs had no effect on the devel-
opment of PH in MCTp-treated mice (Fig. 1).
In order to determine whether non hematopoietic stem
cells were responsible for this effect, we purified lineage-
negative BMDC and injected either cell-sorted lin-CD45+
and lin-CD45- to MCTp-treated animals. Briefly, 10 000
flow-sorted and lin-CD45- or 400 000 lin-CD45+ male
eGFP cells (which are equivalent as 2.5 × 106 cells for bone
marrow reconstitution) were injected in MCTp-treated
female mice. As shown on figure 3, lin-CD45- cells injec-
tion reduced significantly the RV/LV + S ratio and the per-
centage of muscularized pulmonary distal vessels but
RVSP were not statistically modified. This reduction of
RV/LV + S ratio and of muscularization was not observed
after lin-CD45+ treatment.
Effects of bone marrow-derived cells on chronic hypoxia -
induced PH
Mice exposed to 10% O2 for 15 days exhibited increases in
RVSP and RV/LV+S similar to those observed in MCTp-
treated mice. The percentage of muscularized pulmonary
vessels was slightly higher in chronically hypoxic mice
than in MCTp-treated mice (42.6 vs. 33.5 %, P < 0.05,
Figs. 4 and 1, respectively). 2.5·106 BMDCs injection 3
days after exposure to hypoxia did not alter the develop-
ment of PH as assessed by RVSP, RV/LV+S, and pulmo-
nary vessel muscularization. Irradiated BMDCs increased
the percentage of muscularized pulmonary vessels and the
RV/LV+S index but do not significantly modified the
RVSP. In view of these results, experiments with purified
lin-CD45+ and lin-CD45- were not performed in this PH
model.
Detection of male bone marrow-derived cells in lungs from 
female recipient mice
To quantify bone marrow cell engraftment in female
recipient mice, we performed quantitative real-time PCR
on various total lung DNA samples. In DNA samples from
female mice given both MCTp and male BMDCs, about
0.2% of total DNA was of male origin (Fig. 5, panels A and
B), demonstrating that the graft was able to localize in the
lung of these animals but in very few cells. In contrast, no
or very low male DNA was detected in mice given both
MCTp and irradiated male BMDCs.
Detection of GFP-positive bone marrow-derived cells in 
lungs from recipient mice
Immunohistochemical analysis of lung sections from
control eGFP-positive mice revealed strong immunostain-Respiratory Research 2007, 8:8 http://respiratory-research.com/content/8/1/8
Page 4 of 13
(page number not for citation purposes)
A. Ratio of right ventricle to left ventricle + septum weight [RV/(LV+S)] on day 15 in control untreated mice, MCTp-treated  mice, MCTp-treated mice injected with bone marrow-derived cells (BMDCs), and MCTp-treated mice injected with irradiated  BMDCs Figure 1
A. Ratio of right ventricle to left ventricle + septum weight [RV/(LV+S)] on day 15 in control untreated mice, MCTp-treated 
mice, MCTp-treated mice injected with bone marrow-derived cells (BMDCs), and MCTp-treated mice injected with irradiated 
BMDCs. Values are means ± SEM for 6 animals in each group except control mice (n = 15). B. Right ventricular systolic pres-
sure (RVSP) on day 15 in control untreated mice, MCTp-treated mice, MCTp-treated mice injected with BMDCs, and MCTp-
treated mice injected with irradiated BMDCs. Values are means ± SEM for 5 animals in each group except control mice (n = 8). 
C. Percentage of muscularized intraacinar vessels in lungs on day 15 in control untreated mice, MCTp-treated mice, MCTp-
treated mice injected with BMDCs, and MCTp-treated mice injected with irradiated BMDCs. The percentage of pulmonary 
vessels in each muscularization category was determined by dividing the number of vessels in that category by the total number 
counted in the same experimental group. Values are means ± SEM for 5 animals in each group except control mice (n = 11). D. 
Representative panels of proximal artery remodeling. D1) normal artery in a control mouse; D2) MCTp-treated mouse with 
smooth muscle cell proliferation; D3) MCTp-treated mouse injected with bone marrow-derived cells (BMDCs) showing recov-
ery of a nearly normal arterial morphology; D4) MCTp-treated mice injected with irradiated BMDCs showing no amelioration 
of remodeling or SMC proliferation. Sections were stained with hematoxylin-phloxine-saffron. Original magnification ×500.Respiratory Research 2007, 8:8 http://respiratory-research.com/content/8/1/8
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Effect of the number of bone marrow-derived cells on the increases in right ventricular systolic pressure (RVSP) and right ven- tricle to left ventricle + septum weight [RV/(LV+S)] after MCTp injection: 12·106 cells (2 male donor mice for 1 female recipi- ent), 2.5·106 cells (1 male donor mouse for 1 female recipient), or 3.5·105 cells (1/2 male donor mouse sample for 1 female  recipient). Values are means ± SEM for 5 animals in each group Figure 2
Effect of the number of bone marrow-derived cells on the increases in right ventricular systolic pressure (RVSP) and right ven-
tricle to left ventricle + septum weight [RV/(LV+S)] after MCTp injection: 12·106 cells (2 male donor mice for 1 female recipi-
ent), 2.5·106 cells (1 male donor mouse for 1 female recipient), or 3.5·105 cells (1/2 male donor mouse sample for 1 female 
recipient). Values are means ± SEM for 5 animals in each group.Respiratory Research 2007, 8:8 http://respiratory-research.com/content/8/1/8
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A. Ratio of right ventricle to left ventricle + septum weight [RV/(LV+S)] on day 15 in control untreated mice, MCTp-treated  mice, MCTp-treated mice injected with Lin-/CD45- selected cells, and MCTp-treated mice injected with Lin-/CD45+ selected  cells Figure 3
A. Ratio of right ventricle to left ventricle + septum weight [RV/(LV+S)] on day 15 in control untreated mice, MCTp-treated 
mice, MCTp-treated mice injected with Lin-/CD45- selected cells, and MCTp-treated mice injected with Lin-/CD45+ selected 
cells. Values are means ± SEM for 6 animals in each group. B. Right ventricular systolic pressure (RVSP) on day 15 in control 
untreated mice, MCTp-treated mice, MCTp-treated mice injected with Lin-/CD45- selected cells, and MCTp-treated mice 
injected with Lin-/CD45+ selected cells. Values are means ± SEM for 5 animals in each group. C. Percentage of muscularized 
intraacinar vessels in lungs on day 15 in control untreated mice, MCTp-treated mice, MCTp-treated mice injected with Lin-/
CD45- selected cells, and MCTp-treated mice injected with Lin-/CD45+ selected cells. The percentage of pulmonary vessels in 
each muscularization category was determined by dividing the number of vessels in that category by the total number counted 
in the same experimental group. Values are means ± SEM for 6 animals in each group.Respiratory Research 2007, 8:8 http://respiratory-research.com/content/8/1/8
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A. Ratio of right ventricle to left ventricle + septum weight [RV/(LV+S)] on day 15 in control untreated mice, hypoxia-exposed  mice, hypoxia-exposed mice injected with bone marrow-derived cells (BMDCs), and hypoxia-exposed mice injected with irra- diated BMDCs Figure 4
A. Ratio of right ventricle to left ventricle + septum weight [RV/(LV+S)] on day 15 in control untreated mice, hypoxia-exposed 
mice, hypoxia-exposed mice injected with bone marrow-derived cells (BMDCs), and hypoxia-exposed mice injected with irra-
diated BMDCs. Values are means ± SEM for 6 animals in each group except control mice (n = 11). B. Right ventricular systolic 
pressure (RVSP) on day 15 in control untreated mice, hypoxia-exposed mice, hypoxia-exposed mice injected with BMDCs, and 
hypoxia-exposed mice injected with irradiated BMDCs. Values are means ± SEM for 6 animals in each group. C. Percentage of 
muscularized intraacinar vessels in lungs on day 15 in control untreated mice, hypoxia-exposed mice, hypoxia-exposed mice 
injected with BMDCs, and hypoxia-exposed mice injected with irradiated BMDCs. The percentage of pulmonary vessels in 
each muscularization category was determined by dividing the number of vessels in that category by the total number counted 
in the same experimental group. Values are means ± SEM for 5 animals in each group except control mice (n = 10). D. Repre-
sentative panels of proximal artery remodeling. D1) normal artery from a control mouse; D2) hypoxia-exposed mouse with 
SMC proliferation; D3) hypoxia-exposed mouse injected with BMDCs, with no evidence of recovery of normal arterial mor-
phology; D4) hypoxia-exposed mouse injected with irradiated BMDCs, with no improvement in remodeling or SMC prolifera-
tion. Sections were stained with hematoxylin-phloxine-saffron. Original magnification ×500.Respiratory Research 2007, 8:8 http://respiratory-research.com/content/8/1/8
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Panels A and B: Quantification of bone marrow-derived cells (BMDCs) engraftment in recipient mouse lung by real-time quan- titative PCR Figure 5
Panels A and B: Quantification of bone marrow-derived cells (BMDCs) engraftment in recipient mouse lung by real-time quan-
titative PCR. A) Relationship between the threshold cycle number and the percentage of male genomic DNA in the samples. 
The standard curve was generated by using samples containing 100 ng to 0.01 ng of male genomic DNA (losanges). Triangles: 
DNA from MCTp-treated mice injected with BMDCs 3 days later; squares: DNA from MCTp-treated mice injected with irra-
diated BMDCs 3 days later; stars : DNA from hypoxia-treated mice injected with BMDCs 3 days later. B) Histogram of the 
above-reported data showing the percentage of male genomic DNA in lung tissue from female mice treated with MCTp, MCTp 
followed by BMDCs (black bar), or MCTp followed by irradiated BMDCs (open bar) and hypoxia followed by BMDCs. Values 
are means ± SEM for 5 animals in each group.Respiratory Research 2007, 8:8 http://respiratory-research.com/content/8/1/8
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ing throughout the pulmonary parenchyma and vessels
(Fig. 6 panel A and B). No staining was observed in lung
sections from control C57BL/6 mice that did receive
eGFP-positive BMDCs (Fig. 6, panel C). In contrast, lung
sections from mice given both MCTp and eGFP-positive
BMDCs (Fig. 6, panels D, E, F and G) showed staining in
the bronchi, alveolar wall, and distal vessels 5 and 15 days
after MCTp injection.
No eGFP immunostaining was detected in lung sections
from chronically hypoxic mice given the same amount of
eGFP-positive BMDCs (Fig. 6, panel H). Moreover, nor
staining was noticed in MCTp-treated mice injected with
eGFP-positive irradiated BMDCs (data not shown), nor
was DNA detected in these mice using PCR approach. To
investigate whether eGFP-positive cells were present in
systemic organs, we performed immunohistochemical
studies of liver and kidney tissue from MCTp- and
hypoxia-exposed animals given eGFP-positive BMDCs.
No staining was found in these organs (data not shown).
Using dual immunofluorescence with GFP antibody and
CD31, CD45 or pan-cytokeratin antibodies, we were not
able to indicate the phenotype of these engrafted cells
which could be endothelial, hematopoietic or stromal cell
types (data not shown).
Effect of bone marrow-derived cells on eNOS expression
To evaluate the possible impact of BMDCs on the pulmo-
nary endothelium lesions, we measured eNOS protein
levels by immunoblotting in lungs from mice exposed to
MCTp or hypoxia after BMDC injection. As shown in Fig.
7, eNOS protein levels were decreased in lungs from mice
given MCTp, compared to controls, but not in mice given
both MCTp and BMDCs. No alterations in lung eNOS
protein levels were found in chronically hypoxic mice.
Discussion
The present results show that administration of BMDCs
protected against pulmonary hypertension in mice
exposed to MCTp. The increase in lung eNOS expression
suggest that BMDCs exerted protective effects on the
endothelial cell layer of the pulmonary vessels but the
detection of a low percentage of donor cells does not give
conviction about the mechanisms of this beneficial effect.
Our result show that BMDCs failed to improve hypoxia-
induced PH, which, in contrast to MCTp-induced PH, is
not preceded by acute endothelial injury.
Whether BMDCs contribute to the prevention or repair of
pulmonary vascular injury is an important issue. In the
present study, we used MCTp to induce pulmonary vascu-
lar injury and subsequent PH in mice. Because BMDCs
injected after MCTp exposure protected against PH, it is
likely that BMDCs exerted their beneficial effect by limit-
ing the extent of the initial toxicity and vascular injury
induced by MCTp.
We first investigated whether lung cell colonization could
account for the protective effects of BMDCs. To minimize
the risk of interpretation bias, we used different methods
to detect donor cells in the lung. Using male DNA ampli-
fication by quantitative real-time PCR, we detected donor
cells in mouse lungs 12 days after BMDC injection. How-
ever, the percentage of engrafted cells in lung is low as
noted in the quantitative PCR results and the immunos-
taining results. In mice given BMDCs but no MCTp and in
those given irradiated BMDCs and MCTp, no evidence of
donor cell engraftment was obtained. This lack of detec-
tion has to be taken with caution and is probably depend-
ent of the sensitivity of the techniques. Unfortunately we
were not able to discriminate the phenotype of these
engrafted cells with the single dual immunofluorescence
assay used. It is very difficult to phenotype precisely cells
in the lung and this explain for the most part the contro-
versial results published about bone marrow cell plasticity
in the lung. Others experiments such as confocal/decon-
volution microscopy, FACS assays or even use of lineage-
specific reporters should be performed to attend to phe-
notype cells in the alveolar region. Interestingly, using our
MCTp model of PH, we found that lin-CD45+ do not have
a beneficial effect suggesting in our model a differentia-
tion potential of non hematopoietic stem cells. Because of
the literature focusing on the potential effect of endothe-
lial progenitors, we did not perform Lin + cells experi-
ment. Recently Cappocia and col [18] demonstrate that
CD11b+ cells could be responsible of angiogenesis via a
paracrine effect. In our model, we cannot rule out a poten-
tial beneficial effect of Lin + cells.
The importance of endothelial progenitor cells in protect-
ing against PH has previously been addressed by two stud-
ies. Nagaya et al. [19] explored the effect of human
cultured umbilical endothelial progenitor cells 3 days
after MCT-induced injury in nude rats and showed a ben-
eficial effect only when progenitor cells were transfected
with adrenomedullin. More recently, Zhao et al. [9]
reported a protective effect of rat endothelial progenitor
cells in an MCT rat model, as well as an increase of this
beneficial effect when cells were transfected with the e-
NOS gene. Both studies confirmed an engraftment of pro-
genitor cells but to a low level. In addition, others trans-
fection studies using smooth muscle cells and fibroblasts
gave also beneficial effects in these animal models
[20,21]. All these results do not give evidence for a direct
role of endothelial progenitor cells in the improvement of
PH. In animals injected with MCTp, eNOS expression was
markedly decreased. These results are consistent with pre-
vious studies showing that MCTp toxicity is associated
with endothelial damage and reduced eNOS expression inRespiratory Research 2007, 8:8 http://respiratory-research.com/content/8/1/8
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eGFP staining in representative lung panels Figure 6
eGFP staining in representative lung panels. Representative panel of a control mouse lung (A and B) constitutively expressing 
GFP and wild-type mouse lung (C) injected with eGFP bone marrow-derived cells (BMDCs). Panels D, E, F and G are repre-
sentative panels of recipient mouse lung 12 days after injection with eGFP BMDCs, which occurred 3 days after acute lung 
injury by a single administration of MCTp. Staining was detected in few cells in alveolar space, bronchial and distal arteries. 
Panel H. representative panel of recipient mouse lung exposed to hypoxia for 15 days and 12 days after injection with eGFP 
BMDCs: no staining was detected. Original magnification ×125 (A, D and H) ×500 (B, C, E, F and G).Respiratory Research 2007, 8:8 http://respiratory-research.com/content/8/1/8
Page 11 of 13
(page number not for citation purposes)
Western blot analysis of eNOS in lung tissues Figure 7
Western blot analysis of eNOS in lung tissues. A) Representative blot of eNOS protein. B) Quantification of eNOS immunore-
activity in lung homogenates from control untreated mice (vehicle), MCTp-treated mice, MCTp-treated mice injected with 
bone marrow-derived cells (BMDCs), hypoxia-exposed mice, and hypoxia-exposed mice injected with BMDCs. Values are 
means ± SEM for 5 animals in each group.Respiratory Research 2007, 8:8 http://respiratory-research.com/content/8/1/8
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the pulmonary vasculature. Interestingly, in animals
treated with MCTp and injected with BMDCs, eNOS
expression was not decreased and did not differ from that
in control animals. These results again support the
hypothesis that BMDCs limited MCTp-induced endothe-
lial damage or improved endothelial repair.
To investigate whether BMDCs protected against the pul-
monary vascular remodeling process, irrespective of the
cause of PH, we also examined the effects of BMDC injec-
tion in mice with developing hypoxia-induced PH. Inter-
estingly, BMDC injection did not improve PH in this
model. Moreover, we were unable to detect lung cell
engraftment or changes in eNOS expression in mice
exposed to chronic hypoxia. Hypoxia-induced PH, in con-
trast to MCTp-induced PH, is not preceded by acute vascu-
lar injury. The dissimilar effects of BMDCs injection on
PH in these two models are therefore consistent with the
hypothesis that BMDCs exerted their protective effects
and prevented PH by limiting the extent of MCTp-induced
vascular injury or enhancing endothelial repair. Another
reason for the lack of benefits in hypoxic mice may be
related to the increase in circulating progenitor cells dur-
ing hypoxia, as suggested by previous studies[22]. C-kit+
cells were mobilized in calves subjected to hypoxia and
were detected in peripheral blood and in remodeled pul-
monary vessels [23]. In addition, Hayashida et al. [10]
identified BMDCs in pulmonary arteries from mice sub-
jected to BM transplantation followed by hypoxia expo-
sure. These studies suggested that BMDCs might be
mobilized during exposure to hypoxia and concomitant
development of PH. Whether BMDCs contributed to or
protected against hypoxia-induced PH could not be deter-
mined from these studies. In our study, BMDCs injection
did not improve hypoxia-induced PH, suggesting a lim-
ited role as compared to MCTp-induced PH.
In conclusion, our study supports a beneficial effect of
BMDCs infusion in a novel mouse model of pulmonary
vascular injury and hypertension, model that was adapted
from the well-known MCT rat model. The absence of ben-
efits in hypoxia-induced PH suggests that initial vascular
injury may be necessary to obtain a beneficial effect and
to improve repair in the lung. However, the detection of a
low engraftment of cells and the results obtained from
BMDC purified stem cells injection in our model did not
give insight into the mechanisms involved in this benefi-
cial effect.
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